Development of anthracycline-induced dilated cardiomyopathy due to mutation on LMNA gene in a breast cancer patient: a case report.
Jock Chichaco KurucArmando A Durant-ArchiboldJorge MottaK S RaoBarry TrachtenbergCarlos RamosHongyu WangDavid GorensteinFredrik VannbergKing JordanPublished in: BMC cardiovascular disorders (2019)
This case report suggests for the first time a potential genetic predisposition for anthracyclines induced cardiomyopathy in patients with mutations in LMNA gene. Perhaps chemotherapies accelerate or deliver the "second-hit" in the development of DCM in patients with genetic mutations. More data is needed to understand the contribution of LMNA variants that predispose to DCM in patients receiving cardiotoxic therapies.
Keyphrases
- copy number
- case report
- genome wide
- high glucose
- diabetic rats
- muscular dystrophy
- drug induced
- heart failure
- dna methylation
- endothelial cells
- electronic health record
- machine learning
- big data
- oxidative stress
- transcription factor
- climate change
- genome wide identification
- human health
- genome wide analysis
- data analysis